Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nadunolimab + azacitidine
- Development stage
- Unknown
- Lead developer
- Cantargia
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
nadunolimab + azacitidine (CAN04 + azacitidine) is an investigational combination regimen consisting of nadunolimab (CAN04), a fully humanized monoclonal antibody targeting interleukin-1 receptor accessory protein (IL1RAP), and azacitidine, a small-molecule hypomethylating chemotherapy agent. Developed by Cantargia AB, nadunolimab works by blocking IL-1α and IL-1β signaling and inducing antibody-dependent cellular cytotoxicity (ADCC) against IL1RAP-expressing cells, such as leukemia stem cells. Azacitidine acts as an antimetabolite and epigenetic modulator. The combination is being evaluated in clinical trials, including an investigator-initiated Phase 1b/2a trial at MD Anderson Cancer Center, for the treatment of high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
- Other names
- CAN-04 + azacitidineCAN-04 + VidazaCAN04 + azacitidineCAN04 + Vidazanadunolimab + Vidaza
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)IL1RAP (Interleukin 1 receptor accessory protein)
Beyond the preview
Go deeper on nadunolimab + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nadunolimab + azacitidine.